Wells Fargo Raises Kyverna Therapeutics (KYTX) PT to $27 on Confidence in KYV-101 Stiff Person Syndrome Trial Readout

Core Insights - Kyverna Therapeutics Inc. is recognized as a promising young stock with significant upside potential, with Wells Fargo raising its price target to $27 from $24 while maintaining an Overweight rating [1][3] - The firm believes that the market underestimates the de-risked nature of the pivotal trial for KYV-101 in stiff person syndrome, expected to read out in H1 2026 [2][3] Company Overview - Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies for autoimmune diseases, specifically utilizing KYV-101, a fully human, autologous CD19 CAR T-cell therapy [4] Clinical Trial Insights - Updated data from Phase 1 investigator-initiated trials of KYV-101 in progressive multiple sclerosis will be presented at the 2025 ECTRIMS Congress in Barcelona [2] - KYV-101 has shown a tolerable safety profile across both IITs, with no high-grade Cytokine Release Syndrome or Immune Effector Cell Associated Neurotoxicity Syndrome events reported, and no serious adverse events in the Stanford study [3]